HEADER TRANSCRIPTION 28-MAY-09 3HM1 TITLE CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING TITLE 2 DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN TITLE 3 1 NR BOX II PEPTIDE AND ESTRONE ((8R,9S,13S,14S)-3-HYDROXY-13-METHYL- TITLE 4 7,8,9,11,12,14,15,16-OCTAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-17-ONE) COMPND MOL_ID: 1; COMPND 2 MOLECULE: ESTROGEN RECEPTOR; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: ER, ESTRADIOL RECEPTOR, ER-ALPHA, NUCLEAR RECEPTOR SUBFAMILY COMPND 5 3 GROUP A MEMBER 1; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: NUCLEAR RECEPTOR COACTIVATOR 2; COMPND 10 CHAIN: C, D; COMPND 11 SYNONYM: NCOA-2, TRANSCRIPTIONAL INTERMEDIARY FACTOR 2; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: ESR, ESR1, NR3A1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: MCSG7; SOURCE 11 MOL_ID: 2; SOURCE 12 SYNTHETIC: YES KEYWDS ESTROGEN RECEPTOR, LBD, GRIP PEPTIDE, ESTRONE, ALTERNATIVE SPLICING, KEYWDS 2 DNA-BINDING, GLYCOPROTEIN, LIPID-BINDING, METAL-BINDING, NUCLEUS, KEYWDS 3 PHOSPHOPROTEIN, POLYMORPHISM, RECEPTOR, STEROID-BINDING, KEYWDS 4 TRANSCRIPTION, TRANSCRIPTION REGULATION, ZINC, ZINC-FINGER, KEYWDS 5 ACTIVATOR, HORMONE, NUCLEAR RECEPTOR EXPDTA X-RAY DIFFRACTION AUTHOR S.S.RAJAN,Y.KIM,K.VANEK,M.LIWANAG,A.JOACHIMIAK,G.L.GREENE REVDAT 4 20-NOV-24 3HM1 1 REMARK REVDAT 3 06-SEP-23 3HM1 1 REMARK REVDAT 2 13-OCT-21 3HM1 1 REMARK SEQADV LINK REVDAT 1 02-JUN-10 3HM1 0 JRNL AUTH S.S.RAJAN,Y.KIM,K.VANEK,A.JOACHIMIAK,G.L.GREENE JRNL TITL CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA JRNL TITL 2 LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID JRNL TITL 3 RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTRONE JRNL TITL 4 ((8R,9S,13S,14S)-3-HYDROXY-13-METHYL-7,8,9,11,12,14,15, JRNL TITL 5 16-OCTAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-17-ONE) JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 2.33 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.33 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 33.37 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.330 REMARK 3 COMPLETENESS FOR RANGE (%) : 86.0 REMARK 3 NUMBER OF REFLECTIONS : 18884 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.234 REMARK 3 R VALUE (WORKING SET) : 0.231 REMARK 3 FREE R VALUE : 0.289 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.120 REMARK 3 FREE R VALUE TEST SET COUNT : 966 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 33.3711 - 4.4508 0.90 2734 158 0.1977 0.2461 REMARK 3 2 4.4508 - 3.5340 0.82 2412 148 0.1997 0.2539 REMARK 3 3 3.5340 - 3.0876 0.93 2769 149 0.2473 0.3376 REMARK 3 4 3.0876 - 2.8055 1.00 2932 163 0.2431 0.3288 REMARK 3 5 2.8055 - 2.6045 0.93 2792 146 0.3180 0.3428 REMARK 3 6 2.6045 - 2.4510 0.91 2707 117 0.2711 0.3147 REMARK 3 7 2.4510 - 2.3300 0.53 1572 85 0.2493 0.3590 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : 0.31 REMARK 3 B_SOL : 42.61 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.390 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : NULL REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.006 NULL REMARK 3 ANGLE : NULL NULL REMARK 3 CHIRALITY : NULL NULL REMARK 3 PLANARITY : NULL NULL REMARK 3 DIHEDRAL : NULL NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 4 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: CHAIN A REMARK 3 ORIGIN FOR THE GROUP (A): 14.1053 0.1688 -1.0511 REMARK 3 T TENSOR REMARK 3 T11: 0.3975 T22: 0.3626 REMARK 3 T33: 0.3470 T12: -0.0006 REMARK 3 T13: 0.0375 T23: 0.0002 REMARK 3 L TENSOR REMARK 3 L11: 3.2553 L22: 2.5424 REMARK 3 L33: 4.6056 L12: 0.1716 REMARK 3 L13: 0.1936 L23: 0.1401 REMARK 3 S TENSOR REMARK 3 S11: 0.0184 S12: 0.3588 S13: -0.0674 REMARK 3 S21: -0.2159 S22: -0.0560 S23: 0.1096 REMARK 3 S31: 0.0633 S32: -0.2469 S33: -0.0002 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: CHAIN B REMARK 3 ORIGIN FOR THE GROUP (A): 5.9991 -0.6990 22.8697 REMARK 3 T TENSOR REMARK 3 T11: 0.3738 T22: 0.3929 REMARK 3 T33: 0.3376 T12: 0.0162 REMARK 3 T13: -0.0030 T23: 0.0403 REMARK 3 L TENSOR REMARK 3 L11: 4.3839 L22: 1.4519 REMARK 3 L33: 2.6430 L12: -0.1419 REMARK 3 L13: -0.2160 L23: 0.0036 REMARK 3 S TENSOR REMARK 3 S11: 0.0188 S12: -0.2871 S13: 0.0192 REMARK 3 S21: 0.0446 S22: -0.0025 S23: 0.0940 REMARK 3 S31: -0.1126 S32: 0.0055 S33: 0.0000 REMARK 3 TLS GROUP : 3 REMARK 3 SELECTION: CHAIN C REMARK 3 ORIGIN FOR THE GROUP (A): 9.6964 -18.0468 -10.7312 REMARK 3 T TENSOR REMARK 3 T11: 1.5393 T22: 0.6381 REMARK 3 T33: 1.0818 T12: -0.1864 REMARK 3 T13: 0.0501 T23: -0.2340 REMARK 3 L TENSOR REMARK 3 L11: 0.0091 L22: 0.0048 REMARK 3 L33: 0.0061 L12: 0.0104 REMARK 3 L13: 0.0285 L23: -0.0009 REMARK 3 S TENSOR REMARK 3 S11: 0.0307 S12: 0.1869 S13: -0.4125 REMARK 3 S21: -0.3037 S22: 0.0846 S23: 0.2772 REMARK 3 S31: 0.1377 S32: -0.2072 S33: -0.0004 REMARK 3 TLS GROUP : 4 REMARK 3 SELECTION: CHAIN D REMARK 3 ORIGIN FOR THE GROUP (A): -3.2724 15.8709 27.9757 REMARK 3 T TENSOR REMARK 3 T11: 1.0305 T22: 0.5757 REMARK 3 T33: 1.0592 T12: -0.0151 REMARK 3 T13: 0.0688 T23: -0.3221 REMARK 3 L TENSOR REMARK 3 L11: 0.3385 L22: 0.1316 REMARK 3 L33: 0.3297 L12: 0.1622 REMARK 3 L13: -0.3346 L23: -0.2455 REMARK 3 S TENSOR REMARK 3 S11: 0.1964 S12: -0.3749 S13: 0.9338 REMARK 3 S21: -0.1301 S22: 0.2252 S23: 0.5649 REMARK 3 S31: -0.7199 S32: -0.4393 S33: 0.0076 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3HM1 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 08-JUL-09. REMARK 100 THE DEPOSITION ID IS D_1000053299. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 27-FEB-09 REMARK 200 TEMPERATURE (KELVIN) : 77 REMARK 200 PH : 8.3 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 19-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.979 REMARK 200 MONOCHROMATOR : SI(III) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 315 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XFIT, HKL-3000 REMARK 200 DATA SCALING SOFTWARE : HKL-3000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 18967 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.330 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 86.3 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : 0.07200 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.33 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.38 REMARK 200 COMPLETENESS FOR SHELL (%) : 45.2 REMARK 200 DATA REDUNDANCY IN SHELL : 2.50 REMARK 200 R MERGE FOR SHELL (I) : 0.20400 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 4.900 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: XFIT REMARK 200 STARTING MODEL: PDB 2G50 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 41.62 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.11 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.15 M POTASSIUM BROMIDE 30 %W/V REMARK 280 POLYETHYLENE GLYCOL MME 2000 , PH 8.3, VAPOR DIFFUSION, SITTING REMARK 280 DROP, TEMPERATURE 289K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 41.33300 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TETRAMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5360 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 20390 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -30.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ILE A 298 REMARK 465 LYS A 299 REMARK 465 ARG A 300 REMARK 465 SER A 301 REMARK 465 LYS A 302 REMARK 465 LYS A 303 REMARK 465 ASN A 304 REMARK 465 SER A 305 REMARK 465 LEU A 462 REMARK 465 SER A 463 REMARK 465 SER A 464 REMARK 465 THR A 465 REMARK 465 LEU A 466 REMARK 465 LYS A 467 REMARK 465 SER A 468 REMARK 465 LEU A 469 REMARK 465 LEU A 549 REMARK 465 HIS A 550 REMARK 465 ILE B 298 REMARK 465 LYS B 299 REMARK 465 ARG B 300 REMARK 465 SER B 301 REMARK 465 LYS B 302 REMARK 465 SER B 463 REMARK 465 SER B 464 REMARK 465 THR B 465 REMARK 465 LEU B 466 REMARK 465 LYS B 467 REMARK 465 SER B 468 REMARK 465 LEU B 469 REMARK 465 GLU B 470 REMARK 465 GLU B 471 REMARK 465 LYS C 686 REMARK 465 SER C 697 REMARK 465 SER C 698 REMARK 465 LYS D 686 REMARK 465 HIS D 687 REMARK 465 SER D 697 REMARK 465 SER D 698 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 323 132.14 -38.19 REMARK 500 GLU A 330 38.87 -94.65 REMARK 500 PRO A 333 9.08 -60.49 REMARK 500 THR A 371 150.88 -48.62 REMARK 500 GLU B 330 41.36 -79.14 REMARK 500 MET B 396 -76.27 -39.39 REMARK 500 GLU B 397 36.97 -83.98 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE J3Z B 1 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE J3Z A 2 DBREF 3HM1 A 298 550 UNP P03372 ESR1_HUMAN 298 550 DBREF 3HM1 B 298 550 UNP P03372 ESR1_HUMAN 298 550 DBREF 3HM1 C 686 698 UNP Q9WUI9 NCOA2_RAT 686 698 DBREF 3HM1 D 686 698 UNP Q9WUI9 NCOA2_RAT 686 698 SEQADV 3HM1 SER A 537 UNP P03372 TYR 537 ENGINEERED MUTATION SEQADV 3HM1 SER B 537 UNP P03372 TYR 537 ENGINEERED MUTATION SEQRES 1 A 253 ILE LYS ARG SER LYS LYS ASN SER LEU ALA LEU SER LEU SEQRES 2 A 253 THR ALA ASP GLN MET VAL SER ALA LEU LEU ASP ALA GLU SEQRES 3 A 253 PRO PRO ILE LEU TYR SER GLU TYR ASP PRO THR ARG PRO SEQRES 4 A 253 PHE SER GLU ALA SER MET MET GLY LEU LEU THR ASN LEU SEQRES 5 A 253 ALA ASP ARG GLU LEU VAL HIS MET ILE ASN TRP ALA LYS SEQRES 6 A 253 ARG VAL PRO GLY PHE VAL ASP LEU THR LEU HIS ASP GLN SEQRES 7 A 253 VAL HIS LEU LEU GLU CME ALA TRP LEU GLU ILE LEU MET SEQRES 8 A 253 ILE GLY LEU VAL TRP ARG SER MET GLU HIS PRO GLY LYS SEQRES 9 A 253 LEU LEU PHE ALA PRO ASN LEU LEU LEU ASP ARG ASN GLN SEQRES 10 A 253 GLY LYS CME VAL GLU GLY MET VAL GLU ILE PHE ASP MET SEQRES 11 A 253 LEU LEU ALA THR SER SER ARG PHE ARG MET MET ASN LEU SEQRES 12 A 253 GLN GLY GLU GLU PHE VAL CYS LEU LYS SER ILE ILE LEU SEQRES 13 A 253 LEU ASN SER GLY VAL TYR THR PHE LEU SER SER THR LEU SEQRES 14 A 253 LYS SER LEU GLU GLU LYS ASP HIS ILE HIS ARG VAL LEU SEQRES 15 A 253 ASP LYS ILE THR ASP THR LEU ILE HIS LEU MET ALA LYS SEQRES 16 A 253 ALA GLY LEU THR LEU GLN GLN GLN HIS GLN ARG LEU ALA SEQRES 17 A 253 GLN LEU LEU LEU ILE LEU SER HIS ILE ARG HIS MET SER SEQRES 18 A 253 ASN LYS GLY MET GLU HIS LEU TYR SER MET LYS CME LYS SEQRES 19 A 253 ASN VAL VAL PRO LEU SER ASP LEU LEU LEU GLU MET LEU SEQRES 20 A 253 ASP ALA HIS ARG LEU HIS SEQRES 1 B 253 ILE LYS ARG SER LYS LYS ASN SER LEU ALA LEU SER LEU SEQRES 2 B 253 THR ALA ASP GLN MET VAL SER ALA LEU LEU ASP ALA GLU SEQRES 3 B 253 PRO PRO ILE LEU TYR SER GLU TYR ASP PRO THR ARG PRO SEQRES 4 B 253 PHE SER GLU ALA SER MET MET GLY LEU LEU THR ASN LEU SEQRES 5 B 253 ALA ASP ARG GLU LEU VAL HIS MET ILE ASN TRP ALA LYS SEQRES 6 B 253 ARG VAL PRO GLY PHE VAL ASP LEU THR LEU HIS ASP GLN SEQRES 7 B 253 VAL HIS LEU LEU GLU CME ALA TRP LEU GLU ILE LEU MET SEQRES 8 B 253 ILE GLY LEU VAL TRP ARG SER MET GLU HIS PRO GLY LYS SEQRES 9 B 253 LEU LEU PHE ALA PRO ASN LEU LEU LEU ASP ARG ASN GLN SEQRES 10 B 253 GLY LYS CME VAL GLU GLY MET VAL GLU ILE PHE ASP MET SEQRES 11 B 253 LEU LEU ALA THR SER SER ARG PHE ARG MET MET ASN LEU SEQRES 12 B 253 GLN GLY GLU GLU PHE VAL CYS LEU LYS SER ILE ILE LEU SEQRES 13 B 253 LEU ASN SER GLY VAL TYR THR PHE LEU SER SER THR LEU SEQRES 14 B 253 LYS SER LEU GLU GLU LYS ASP HIS ILE HIS ARG VAL LEU SEQRES 15 B 253 ASP LYS ILE THR ASP THR LEU ILE HIS LEU MET ALA LYS SEQRES 16 B 253 ALA GLY LEU THR LEU GLN GLN GLN HIS GLN ARG LEU ALA SEQRES 17 B 253 GLN LEU LEU LEU ILE LEU SER HIS ILE ARG HIS MET SER SEQRES 18 B 253 ASN LYS GLY MET GLU HIS LEU TYR SER MET LYS CME LYS SEQRES 19 B 253 ASN VAL VAL PRO LEU SER ASP LEU LEU LEU GLU MET LEU SEQRES 20 B 253 ASP ALA HIS ARG LEU HIS SEQRES 1 C 13 LYS HIS LYS ILE LEU HIS ARG LEU LEU GLN ASP SER SER SEQRES 1 D 13 LYS HIS LYS ILE LEU HIS ARG LEU LEU GLN ASP SER SER MODRES 3HM1 CME A 381 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3HM1 CME A 417 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3HM1 CME A 530 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3HM1 CME B 381 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3HM1 CME B 417 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3HM1 CME B 530 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE HET CME A 381 10 HET CME A 417 10 HET CME A 530 10 HET CME B 381 10 HET CME B 417 10 HET CME B 530 10 HET J3Z A 2 20 HET J3Z B 1 20 HETNAM CME S,S-(2-HYDROXYETHYL)THIOCYSTEINE HETNAM J3Z (9BETA,13ALPHA)-3-HYDROXYESTRA-1,3,5(10)-TRIEN-17-ONE HETSYN J3Z ESTRONE FORMUL 1 CME 6(C5 H11 N O3 S2) FORMUL 5 J3Z 2(C18 H22 O2) FORMUL 7 HOH *10(H2 O) HELIX 1 1 LEU A 306 LEU A 310 5 5 HELIX 2 2 THR A 311 ASP A 321 1 11 HELIX 3 3 SER A 338 ARG A 363 1 26 HELIX 4 4 GLY A 366 LEU A 370 5 5 HELIX 5 5 THR A 371 SER A 395 1 25 HELIX 6 6 ASN A 413 CME A 417 5 5 HELIX 7 7 GLY A 420 MET A 438 1 19 HELIX 8 8 GLN A 441 SER A 456 1 16 HELIX 9 9 GLY A 457 PHE A 461 5 5 HELIX 10 10 GLU A 470 ALA A 493 1 24 HELIX 11 11 THR A 496 LYS A 531 1 36 HELIX 12 12 SER A 537 ALA A 546 1 10 HELIX 13 13 THR B 311 ALA B 322 1 12 HELIX 14 14 SER B 338 LYS B 362 1 25 HELIX 15 15 THR B 371 MET B 396 1 26 HELIX 16 16 ASN B 413 VAL B 418 5 6 HELIX 17 17 MET B 421 MET B 438 1 18 HELIX 18 18 GLN B 441 SER B 456 1 16 HELIX 19 19 GLY B 457 PHE B 461 5 5 HELIX 20 20 LYS B 472 ALA B 493 1 22 HELIX 21 21 THR B 496 LYS B 531 1 36 HELIX 22 22 SER B 537 HIS B 547 1 11 HELIX 23 23 LYS C 688 ASP C 696 1 9 HELIX 24 24 LYS D 688 LEU D 694 1 7 SHEET 1 A 2 LYS A 401 ALA A 405 0 SHEET 2 A 2 LEU A 408 ASP A 411 -1 O LEU A 408 N ALA A 405 SHEET 1 B 2 LYS B 401 ALA B 405 0 SHEET 2 B 2 LEU B 408 ASP B 411 -1 O LEU B 408 N ALA B 405 LINK C GLU A 380 N CME A 381 1555 1555 1.33 LINK C CME A 381 N ALA A 382 1555 1555 1.32 LINK C LYS A 416 N CME A 417 1555 1555 1.33 LINK C CME A 417 N VAL A 418 1555 1555 1.33 LINK C LYS A 529 N CME A 530 1555 1555 1.33 LINK C CME A 530 N LYS A 531 1555 1555 1.33 LINK C GLU B 380 N CME B 381 1555 1555 1.32 LINK C CME B 381 N ALA B 382 1555 1555 1.33 LINK C LYS B 416 N CME B 417 1555 1555 1.33 LINK C CME B 417 N VAL B 418 1555 1555 1.33 LINK C LYS B 529 N CME B 530 1555 1555 1.33 LINK C CME B 530 N LYS B 531 1555 1555 1.33 SITE 1 AC1 7 MET B 343 LEU B 346 GLU B 353 ARG B 394 SITE 2 AC1 7 GLY B 521 HIS B 524 LEU B 525 SITE 1 AC2 6 MET A 343 LEU A 346 GLU A 353 GLY A 521 SITE 2 AC2 6 LEU A 525 MET A 528 CRYST1 56.267 82.666 58.989 90.00 109.18 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017772 0.000000 0.006182 0.00000 SCALE2 0.000000 0.012097 0.000000 0.00000 SCALE3 0.000000 0.000000 0.017949 0.00000